We are live on ! Find out more
PCA

Private Capital Advisors Portfolio holdings

AUM $1.14B
1-Year Est. Return 48.66%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+48.66%
3 Year Est. Return
+137.63%
5 Year Est. Return
+227.94%
10 Year Est. Return
+772.14%
AUM
$232M
AUM Growth
-$7.38M
Cap. Flow
-$16.7M
Cap. Flow %
-7.19%
Top 10 Hldgs %
29.39%
Holding
116
New
2
Increased
6
Reduced
34
Closed
9

Top Buys

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$3.76M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$523K
3
PVH icon
PVH
PVH
+$327K
4
CMCSA icon
Comcast
CMCSA
+$58.7K
5
NFLX icon
Netflix
NFLX
+$11.4K

Sector Composition

Rank Sector Weight
1 Healthcare 29.01%
2 Communication Services 22.71%
3 Energy 13.38%
4 Industrials 12.54%
5 Technology 5.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AAPL icon
1
Apple
AAPL
$4.67T
$8.41M 3.63%
319,796
-3,800
-1% -$109K
T icon
2
AT&T
T
$178B
$7.65M 3.3%
294,444
-3,006
-1% -$76.3K
CMCSA icon
3
Comcast
CMCSA
$96B
$7.64M 3.3%
270,718
+1,950
+0.7% +$58.7K
GE icon
4
GE Aerospace
GE
$355B
$7.18M 3.1%
48,107
-251
-0.5% -$35.6K
MCK icon
5
McKesson
MCK
$104B
$6.68M 2.88%
33,874
TMO icon
6
Thermo Fisher Scientific
TMO
$230B
$6.52M 2.81%
45,935
-200
-0.4% -$26.7K
GOOGL icon
7
Alphabet (Google) Class A
GOOGL
$4.24T
$6.25M 2.7%
160,560
-2,800
-2% -$104K
TRIL
8
DELISTED
Trillium Therapeutics Inc.
TRIL
$6M 2.59%
476,069
-2,500
-0.5% -$34.8K
PFE icon
9
Pfizer
PFE
$159B
$5.91M 2.55%
192,818
-84
-0% -$2.64K
EPD icon
10
Enterprise Products Partners
EPD
$84.3B
$5.84M 2.52%
228,279
DHR icon
11
Danaher
DHR
$152B
$5.34M 2.31%
85,537
BX icon
12
Blackstone
BX
$107B
$5.33M 2.3%
182,410
-4,740
-3% -$151K
LYB icon
13
LyondellBasell Industries
LYB
$20.6B
$5.29M 2.29%
60,915
META icon
14
Meta Platforms (Facebook)
META
$1.47T
$5.28M 2.28%
50,423
-550
-1% -$56.5K
UNH icon
15
UnitedHealth
UNH
$353B
$5.17M 2.23%
43,933
-450
-1% -$52.6K
UNP icon
16
Union Pacific
UNP
$183B
$4.85M 2.09%
62,045
LBTYK icon
17
Liberty Global Class C
LBTYK
$3.56B
$4.63M 2%
130,729
-1,152
-0.9% -$41.5K
MMM icon
18
3M
MMM
$89.9B
$4.26M 1.84%
33,787
-48
-0.1% -$6.17K
TVRD
19
Tvardi Therapeutics
TVRD
$24.3M
$4.16M 1.8%
+6,857
New +$3.76M
PARA
20
DELISTED
Paramount Global Class B
PARA
$3.98M 1.72%
84,355
-21,735
-20% -$1.02M
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$424M
$3.86M 1.67%
85,250
+12,000
+16% +$523K
LMT icon
22
Lockheed Martin
LMT
$130B
$3.86M 1.67%
17,775
-4
-0% -$868
CNI icon
23
Canadian National Railway
CNI
$76.2B
$3.75M 1.62%
67,090
-23
-0% -$1.34K
NTI
24
DELISTED
NORTHERN TIER ENERGY LP CLASS A
NTI
$3.69M 1.59%
142,675
-1,500
-1% -$38.8K
TFCFA
25
DELISTED
Twenty-First Century Fox, Inc. Class A
TFCFA
$3.6M 1.55%
132,636
-19,825
-13% -$575K

Similar funds

Private Capital Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Private Capital Advisors held 116 positions worth $232M, down 3.1% from $239M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Private Capital Advisors withdrew a net $16.7M in Q4 2015, closing 9 positions and reducing 34 holdings. Its most notable exit was MacroGenics, an estimated $1.32M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 29% a quarter earlier, followed by Communication Services and Energy.

Against the trend, Private Capital Advisors opened a new position in Tvardi Therapeutics worth $4.16M.

  • Private Capital Advisors's largest Q4 2015 buy was Tvardi Therapeutics: 6,857 shares worth $4.16M.
  • Private Capital Advisors added most to Rocket Pharmaceuticals in Q4 2015, an estimated $523K increase.
  • Private Capital Advisors's biggest Q4 2015 reduction was Applied Genetic Technologies Corporation, cutting an estimated $4.54M.
  • Private Capital Advisors fully exited MacroGenics in Q4 2015, selling an estimated $1.32M.
  • Private Capital Advisors's ten largest holdings make up 29% of its $232M portfolio in Q4 2015.
  • Private Capital Advisors opened 2 new positions and closed 9 in Q4 2015.
  • Private Capital Advisors's portfolio value fell 3.1% quarter-over-quarter to $232M.

Based on Private Capital Advisors's 13F filing for Q4 2015, filed 22 Jan 2016.